Business Context and Reporting Period
Revelation Biosciences, Inc. (REVB), a Delaware corporation and emerging growth company, filed this Form 8-K on January 27, 2022, reporting events occurring on January 23, 2022. The filing details a private placement transaction and related agreements.
Key Financial Metrics
This filing reports on a specific capital raise event rather than periodic financial performance. Key metrics include:
- Gross Proceeds: Approximately $7.76 million.
- Placement Agent Fee: Approximately $465,600 (6.0% of gross proceeds).
- Securities Issued:
- 1,293,126 shares of common stock at $3.00 per share.
- 1,293,541 unregistered pre-funded warrants (funded at $3.00, exercise price $0.00001).
- 2,586,667 unregistered common warrants (exercise price $3.29).
- 362,134 placement agent warrants (7.0% of aggregate shares sold).
The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement and a Registration Rights Agreement. The company closed the private placement on January 25, 2022, resulting in an immediate increase in cash resources and an increase in outstanding equity securities.
Outlook, Commentary, and Risks
Use of Proceeds: Management intends to use net proceeds to advance the company's clinical and preclinical pipeline and for general working capital purposes.
Registration Rights: The company agreed to file a Form S-1 registration statement for the resale of the shares and warrant-issuable shares by January 31, 2022, or no later than February 4, 2022.
Exercise Restrictions:
- Pre-Funded Warrants are subject to a 9.99% beneficial ownership limit (adjustable to 9.99% with notice).
- Common Warrants are subject to a 4.99% beneficial ownership limit (adjustable to 9.99% with notice).
- Common Warrants are exercisable six months after issuance and expire five and one-half years after issuance.
Regulatory Status: The securities were offered pursuant to exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b).
Investor Verification Checklist
- Verify the closing date of January 25, 2022, and the receipt of gross proceeds of approximately $7.76 million.
- Confirm the terms of the pre-funded warrants, specifically the nominal exercise price of $0.00001 and the 9.99% ownership cap.
- Review the timeline for the filing of the Form S-1 registration statement (deadline: February 4, 2022).
- Assess the dilution impact of the 1,293,126 new shares and the potential issuance of up to 4,242,342 shares upon full exercise of all warrants.
- Check subsequent filings for the actual filing date of the Form S-1 and any updates on the clinical pipeline progress funded by this capital.